{"brief_title": "DPPE in Combination With Epirubicin and Cyclophosphamide in the Treatment of Breast Cancer", "brief_summary": "The purpose of this trial is to study DPPE combined with epirubicin and cyclophosphamide in patients with metastatic and/or recurrent breast cancer who may have received previous hormone treatment but have not had exposure to anthracycline treatment. Stratification allocation will be within the following subgroups: 1. Prior cytotoxic treatment; 2. Estrogen receptor status; 3. ECOG performance status; 4. Number of cycles of chemotherapy.", "detailed_description": "Endpoints of the trial are as follows: primary: overall survival; secondary: response rate, progression free survival, toxicity, neurocognitive function.", "condition": ["Breast Cancer", "Metastases"], "intervention_type": ["Drug"], "intervention_name": ["YMB 1002"], "criteria": "Inclusion Criteria: - Histological proof of breast cancer - Documented evidence of metastatic and/or recurrent breast cancer - Presence of at least one bi-dimensional or uni-dimensional lesion - ECOG status 0, 1 or 2 - Quality of life", "gender": "Female", "minimum_age": "16 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Metastatic breast cancer", "mesh_term": ["Breast Neoplasms", "Cyclophosphamide", "Epirubicin"], "id": "NCT00099281"}